Newsfeed

How to help patients to contact their health minister: a case study with PHA Canada
Every week or two there is a news story about another drug, usually an expensive drug, being denied to a person who is part of a provincial drug plan. The news article often cites a Provincial Health Minister’s office as stating that the drug is under review, or they are waiting to sign a contract with the drug company, or there is insufficient evidence to pay for the drug at this time. Meanwhile, the patient is denied the treatment and the medic…
Canadians with rare lung disease are relieved to now have publicly funded access to potentially life-extending treatment
VANCOUVER and HAMILTON, ON, Nov. 30, 2018 /CNW/ - At the end of a successful Pulmonary Hypertension Awareness Month, members of the Pulmonary Hypertension Association of Canada (PHA Canada) and Scleroderma Canada (SC) have come together to thank provincial governments for providing the majority of Canadians with public funding for Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH). In the past month, both British Colum…
B.C. government to fund expensive treatments for hearts failure and liver disease.
The B.C. government has approved the coverage of expensive drugs that will help British Columbians living with heart failure, liver disease or pulmonary arterial hypertension. Health Minister Adrian Dix says the drugs will benefit approximately 950 British Columbians and the estimated overall cost to add these drugs is approximately $21.7 million over the next three years.
British Columbians to benefit from more treatment options
British Columbians living with heart failure, liver disease or pulmonary arterial hypertension now have more treatment options available to them to better manage their condition. Three limited coverage drugs were added to the PharmaCare Special Authority program as of Oct. 30, 2018: ivabradine (Lancora) for the treatment of heart failure obeticholic acid (Ocaliva) for the treatment of liver disease selexipag (Uptravi) for the treatment of…
November is Pulmonary Hypertension Awareness Month
‘Life In Purple’ campaign sheds light on the physical, social, and financial impacts of rare lung disease on over 10,000 Canadians Vancouver, BC (November 14, 2018) — This month, the Pulmonary Hypertension Association of Canada (PHA Canada) is bringing attention to the serious impacts of pulmonary hypertension (PH) on an estimated 10,000 Canadians and their families through their ‘Life In Purple’ campaign. PH is a very complex and serious…
Treprostinil Prevents Cellular Responses Linked to Arterial Remodeling and PAH, Study Reveals
Treprostinil is a therapy that works to reduce pulmonary artery narrowing in people with pulmonary arterial hypertension (PAH) by preventing artery wall remodeling processes. That finding comes from a research study investigating the medicine’s molecular effects using patient lung artery cells suggests. Treprostinil appears to work by stopping artery wall remodeling by inhibiting the release of growth factors, proliferation of cells, and depos…
Serum NLRC3 Levels Identified as Potential Non-invasive Biomarker for PH
Serum NLRC3 levels are markedly lower in patients with pulmonary hypertension, and correlate with results from other diagnostic tests, researchers from China report. This study with that finding, “NLRC3: A Novel Noninvasive Biomarker for Pulmonary Hypertension Diagnosis,” was published in the journal Aging and Disease. Right heart catheterization (RHC), the gold standard diagnostic test for PH, is an invasive examination that requires an ex…
Long-term Benefits of Ralinepag for PAH Patients Shown in Interim Data from Phase 2 Extension Trial
Long-term use of ralinepag, an investigational therapy being developed by Arena Pharmaceuticals, can promote positive changes in the outcome of patients with pulmonary arterial hypertension (PAH), interim data from a Phase 2 extension trial shows. After taking oral ralinepag for a median of up to 1.8 years, patients continued to show significant improvements in their exercise capacity and blood flow in the lung arteries, compared with before t…
Drinking Nitrate-Rich Beetroot Juice May Improve NO Levels in PAH Patients, Small Trial Shows
Drinking nitrate-rich beetroot juice can improve the production of nitric oxide in patients with pulmonary arterial hypertension (PAH), a small clinical trial shows. Data from the trial was reported in the study, “Effects of oral supplementation with nitrate-rich beetroot juice in patients with pulmonary arterial hypertension — results from BEET-PAH an exploratory randomized, double-blind, placebo-controlled crossover study,” published in the …
Why Chair Yoga for People With Pulmonary Hypertension?
Yoga has been practiced for thousands of years, and people who practice yoga have experienced the benefits. Today, yoga is more widely known and practiced, and has become an important part of therapy for a variety of medical conditions. One smaller pilot study in Canada in pulmonary arterial hypertension (PAH) patients revealed some potential at least short-term quality of life improvements as a result of participating in yoga. A 2008 study among…
« Previous123456...44Next »
Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png